Company news
XORTX Therapeutics, Inc. news in 2025
XORTX Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.
XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update
December 31, 2025
XORTX Announces Closing of US$1.1 Million Registered Direct Offering
October 29, 2025
XORTX Announces Pricing of US$1.1 Million Registered Direct Offering
October 21, 2025
XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency
October 20, 2025
XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
October 20, 2025
XORTX Announces Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems
October 17, 2025
Join XORTX for an Exclusive Live Investor Webinar and Q&A Session on September 10
September 4, 2025
XORTX Initiates IND Preparation for XORLO™ in Gout Program
September 3, 2025
XORTX Completes USD $114,500 Private Placement
August 8, 2025
XORTX Provides Corporate Update and Planned Activities for 2025 / 2026
August 7, 2025
XORTX Announces USD $114,500 Private Placement
July 31, 2025
XORTX Completes Non-Brokered Private Placement of Units
July 22, 2025
XORTX Announces USD $925,000 Private Placement
June 26, 2025
XORTX Announces USD $3 Million Offering
May 19, 2025
XORTX Provides Update on FDA Type B Meeting Request
April 30, 2025
XORTX Announces Grant of European Patent
April 28, 2025
XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
April 17, 2025
XORTX Announces Update for Discussion with the FDA
March 19, 2025
XORTX Commences Gout Program NDA Discussions with the FDA
February 24, 2025